Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2021 | $38.00 → $5.00 | Buy → Hold | Jefferies |
| 12/2/2021 | $45.00 → $5.00 | Buy → Underperform | B of A Securities |
| 12/1/2021 | Outperform → Mkt Perform | William Blair | |
| 12/1/2021 | Buy → Neutral | H.C. Wainwright | |
| 9/20/2021 | $100.00 → $65.00 | Buy | HC Wainwright & Co. |
| 9/9/2021 | $50.00 | Outperform | Robert W. Baird |
| 9/9/2021 | $50.00 | Outperform | Baird |
| 8/4/2021 | $100.00 | Neutral → Buy | HC Wainwright & Co. |
Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully dedicated executive leaderDr. Jiangwen (Jen) Majeti, PhD, MBA, current BeyondSpring Director, appointed Vice Chairman — deepening Board-level governance and providing strategic continuityMin Qiu appointed Chief Executive Officer with a clear mandate: execute DUBLIN-4, extend Plinabulin's scientific optionality, and build BeyondSpring's global partner and investor baseNa Li appointed Chief Financial Officer to strengthen BeyondSpring's financial position and support capital mark
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitorsDurable survival benefit: 12-month OS rate of 78.1% and 24-month OS rate of 58.0% in a patient population with limited treatment optionsGood tolerability and immune activation: Along with increased frequencies of activated CD4+/CD8+ T cells post-treatment, hematology test also showed safety benefit with significantly higher levels of WBCs, neutrophils and platelets. FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL. Presentation details are as follows: Title: A Phase 2 Study of Plinabulin (Plin)/Doceta
4 - BeyondSpring Inc. (0001677940) (Issuer)
4 - BeyondSpring Inc. (0001677940) (Issuer)
4 - BeyondSpring Inc. (0001677940) (Issuer)
Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously
B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously
William Blair downgraded BeyondSpring from Outperform to Mkt Perform
8-K - BeyondSpring Inc. (0001677940) (Filer)
10-Q - BeyondSpring Inc. (0001677940) (Filer)
8-K - BeyondSpring Inc. (0001677940) (Filer)
Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully dedicated executive leaderDr. Jiangwen (Jen) Majeti, PhD, MBA, current BeyondSpring Director, appointed Vice Chairman — deepening Board-level governance and providing strategic continuityMin Qiu appointed Chief Executive Officer with a clear mandate: execute DUBLIN-4, extend Plinabulin's scientific optionality, and build BeyondSpring's global partner and investor baseNa Li appointed Chief Financial Officer to strengthen BeyondSpring's financial position and support capital mark
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline
Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors progressed after first line therapy — DUBLIN-3 study results published in The Lancet Respiratory Medicine Confirmatory Trial Planned: Based on DUBLIN-3 Phase 3 data and US FDA discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient population progressed on immune checkpoint inhibitors (NCT07361484)Overcoming Immunotherapy Resistance: Early clinical data at MD A
Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI
SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)
SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)
SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)